In this episode, Marion Elligsen, BScPhm, MSc, RPh, ACPR; Keith S Kaye, MD, MPH; and Andrew Shorr, MD, MPH, MBA, discuss key considerations for selecting empiric antibiotic regimens in patients with HABP/VABP in the intensive care unit, including: The role of novel β-lactam/β-lactamase inhibitor combinationsUse of clinical predictions scores (eg, Drug Resistance in Pneumonia [DRIP] score) to predict risk for pneumonia caused by multidrug-resistant pathogensApplication of rapid diagnostic testing in critically ill patients with pneumonia, including current limitationsImplementation of advanced antibiograms and clinical prediction scoresClinical utility of biomarkers for pneumonia (eg, procalcitonin)Application of updated nosocomial pneumonia classifications in clinical practiceFaculty:Marion Elligsen, BScPhm, MSc, RPh, ACPRPractice-Based ResearcherSunnybrook Research InstituteAntimicrobial Stewardship Pharmacy LeadDepartment of PharmacySunnybrook Health Sciences CentreToronto, Ontario, CanadaKeith S. Kaye, MD, MPHChief Division of Allergy, Immunology and Infectious DiseasesProfessor of MedicineRutgers Robert Wood Johnson Medical SchoolNew Brunswick, New JerseyAndrew Shorr, MD, MPH, MBADirectorPulmonary and Critical Care MedicineMedstar Washington Hospital CenterWashington, DCContent based on a CME program supported by an educational grant from Merck Sharp & Dohme Corp. Link to full program:https://bit.ly/3HaZpYwLink to downloadable slideset:https://bit.ly/3UxHoqr Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related